Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery.
CAMBRIDGE, Mass. and BIRMINGHAM, Ala., May 2,2006,/PRNewswire/– Genzyme Pharmaceuticals, a business unit of Genzyme Corporation, and Brookwood Pharmaceuticals, Inc., today announced a broad collaboration to develop novel drug delivery solutions, with an initial focus on peptide delivery. The partnership offers customized solutions for parenteral formulations by combining expertise in design for peptide delivery, peptide synthesis, and drug delivery technologies.
The 'Design for Peptide Delivery' approach optimizes peptide physical and chemical properties early on in drug development, so as to match a peptide with the properties of microparticles, implants and other drug delivery formulations required for optimal drug delivery. Combining the capabilities and knowledge of Genzyme and Brookwood in parallel design of peptide and delivery systems will result in clients developing sophisticated pharmaceutical products that will benefit the patient.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Arcus’ Quemliclustat Earns Orphan Drug Designation as Phase III Pancreatic Cancer Trial Advances
July 11th 2025The FDA has granted orphan status to Arcus Biosciences’ CD73 inhibitor quemliclustat for metastatic pancreatic cancer, as the global PRISM-1 Phase III trial nears full enrollment following promising survival data from ARC-8.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.